A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

NCT02267863 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Drug manufacturing process and procedure review

Conditions

Acute Myelogenous Leukemia in Relapse
Acute Myelogenous Leukemia, Relapsed, Adult
Acute Myelogenous Leukemia, Adult
Acute Myelogenous Leukemia
High Risk Myelodysplasia

Interventions

DRUG: APTO-253

Sponsor

Aptose Biosciences Inc.